The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Abstract Background Dendritic cells (DCs) are central for the initiation and regulation of
innate and adaptive immunity in the tumor microenvironment. As such, many kinds of DC …

Abstract mRNA vaccines have gained popularity over the last decade as a versatile tool for
developing novel therapeutics. The recent success of coronavirus disease (COVID-19) …

Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the poorest
outcomes, and is associated with a high risk of relapse and metastasis. The treatment …

Despite dramatic advances in cancer research and therapy, breast cancer remains a tricky
health problem and represents a top biomedical research priority. Nowadays, breast cancer …

Breast cancer is a problem for women's health globally. Early detection techniques come in
a variety of forms ranging from local to systemic and from non-invasive to invasive. The …

Breast cancer is the leading cause of death in women from 20 to 59 years old. The
conventional treatment includes surgery, chemotherapy, hormonal therapy, and …

The incidence of breast cancer in younger women is rising. Although early-onset breast
cancer is highly associated with biologically aggressive tumors such as triple-negative and …

Substantial therapeutic advancement has been made in the field of immunotherapy in breast
cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy …